# US 2006/0068000 A1 · Extended release formulation

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2006/0068000 A1
- Document ID: US20060068000A1
- Status: Published application
- Kind: A1
- Application number: 11/280,485
- Filed: 2005-11-16
- Published: 2006-03-30
- Earliest claimed: 1996-03-25
- Assignees: Wyeth
- Inventors: Deborah Sherman; John Clark; John Larner; Steven White
- Web page: https://patentgrep.com/patent/US20060068000A1

## CPC

- A61K 9/1652: {Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin (homeopathic globules A61K9/1623)}
- A61K 9/5047: {Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

This invention relates to a 24 hour extended release dosage formulation and unit dosage form thereof of venlafaxine hydrochloride, an antidepressant, which provides better control of blood plasma levels than conventional tablet formulations which must be administered two or more times a day and further provides a lower incidence of nausea and vomiting than the conventional tablets. More particularly, the invention comprises an extended release formulation of venlafaxine hydrochloride comprising a therapeutically effective amount of venlafaxine hydrochloride in spheroids comprised of venlafaxine hydrochloride, microcrystalline cellulose and, optionally, hydroxypropylmethylcellulose coated with a mixture of ethyl cellulose and hydroxypropylmethylcellulose.

## Claims

### Claim 1

A unit dosage form of a medicament, comprising:
a core comprising a uniform dosage of venlafaxine; and
a degradable coating, characterized in that the coating degrades so that venlafaxine is released in a peak, followed by a protracted, substantially linear decrease.

### Claim 2 (depends on 1)

The unit dosage form of claim 1, characterized in that the coating degrades so that 65-90% of the venlafaxine is released after 12 hours as determined using USP Apparatus 1 at 100 rpm in purified water at 37° C.

### Claim 3 (depends on 1)

The unit dosage form of claim 1, wherein the peak occurs between 4 and 8 hours after administration to a subject.

### Claim 4 (depends on 3)

The unit dosage form of claim 3, wherein the peak is a Cmax.

### Claim 5 (depends on 1)

The unit dosage form of claim 1, wherein the dosage form provides therapeutic blood serum levels of venlafaxine over a period of at least 24 hours.

### Claim 6 (depends on 1)

The unit dosage form of claim 1, wherein the core optionally comprises a low viscosity polymer.

### Claim 7 (depends on 6)

The unit dosage form of claim 6, wherein the core optionally comprises a low viscosity hydrogel.

### Claim 8 (depends on 7)

The unit dosage form of claim 7, wherein the low viscosity hydrogel has a viscosity of less than 10 cps.

### Claim 9 (depends on 1)

The unit dosage form of claim 1, wherein the core comprises about 30 to about 40 percent venlafaxine hydrochloride.

### Claim 10 (depends on 9)

The unit dosage form of claim 9, wherein the core comprises about 50 to about 70 percent microcrystalline cellulose.

### Claim 11 (depends on 1)

The unit dosage form of claim 1, wherein the degradable coating constitutes about 2 to about 12 percent by weight of the unit dosage form.

### Claim 12 (depends on 11)

The unit dosage form of claim 11, wherein the degradable coating constitutes about 5 to about 10 percent by weight of the unit dosage form.

### Claim 13 (depends on 1)

The unit dosage form of claim 1, wherein the core comprises an amount of venlafaxine sufficient to provide an equivalent amount of venlafaxine in one day as compared with two 75 mg doses.

### Claim 14 (depends on 1)

The unit dosage form of claim 1, wherein the core comprises an amount of venlafaxine sufficient to provide an equivalent amount of venlafaxine in one day as compared with three 50 mg doses.

### Claim 15 (depends on 1)

The unit dosage form of claim 1, wherein the core comprises venlafaxine and a binder or filler in the form of an admixture, solid dispersion, or granulation mix.

### Claim 16 (depends on 15)

The unit dosage form of claim 15, wherein the core comprises a granulation mix comprising venlafaxine and a binder or filler.

### Claim 17 (depends on 16)

The unit dosage form of claim 16, wherein the granulation mix comprises venlafaxine hydrochloride and one or more of microcrystalline cellulose, hydroxypropylmethylcellulose, polyvinylpyrrolidone, methylcellulose or PEG.

### Claim 18 (depends on 15)

The unit dosage form of claim 15, wherein the core comprises a solid dispersion comprising venlafaxine and a binder or filler.

### Claim 19 (depends on 18)

The unit dosage form of claim 18, wherein the solid dispersion comprises venlafaxine hydrochloride and one or more of microcrystalline cellulose, hydroxypropylmethylcellulose, polyvinylpyrrolidone, methylcellulose or PEG.

### Claim 20 (depends on 15)

The unit dosage form of claim 15, wherein the core comprises an admixture comprising venlafaxine and a binder or filler.

### Claim 21 (depends on 20)

The unit dosage form of claim 20, wherein the admixture comprises venlafaxine hydrochloride and one or more of microcrystalline cellulose, hydroxypropylmethylcellulose, polyvinylpyrrolidone, methylcellulose or PEG.

### Claim 22 (depends on 1)

The unit dosage form of claim 1, wherein the core comprises an extrudate comprising venlafaxine and a binder or filler.

### Claim 23 (depends on 22)

The unit dosage form of claim 22, wherein the extrudate comprises venlafaxine hydrochloride and one or more of microcrystalline cellulose, hydroxypropylmethylcellulose, polyvinylpyrrolidone, methylcellulose or PEG.

### Claim 24 (depends on 1)

The unit dosage form of claim 1, wherein the core is in the form of spheroids, beads, or cylinders.

### Claim 25 (depends on 24)

The unit dosage form of claim 24, wherein the spheroids, beads, or cylinders comprise venlafaxine hydrochloride and one or more of microcrystalline cellulose, hydroxypropylmethylcellulose, polyvinylpyrrolidone, methylcellulose or PEG.
